Navigation Links
LCSB discovers endogenous antibiotic in the brain
Date:5/6/2013

Luxembourg, 6 May 2013 Scientists from the Luxembourg Centre for Systems Biomedicine (LCSB) of the University of Luxembourg have discovered that immune cells in the brain can produce a substance that prevents bacterial growth: namely itaconic acid. Until now, biologists had assumed that only certain fungi produced itaconic acid. A team working with Dr. Karsten Hiller, head of the Metabolomics Group at LCSB, and Dr. Alessandro Michelucci has now shown that even so-called microglial cells in mammals are also capable of producing this acid. "This is a ground breaking result," says Prof. Dr. Rudi Balling, director of LCSB: "It is the first proof of an endogenous antibiotic in the brain." The researchers have now published their results in the prestigious scientific journal PNAS.

Alessandro Michelucci is a cellular biologist, with focus on neurosciences. This is an ideal combination for LCSB with its focus on neurodegenerative diseases, and Parkinson's disease especially i.e. changes in the cells of the human nervous system. "Little is still known about the immune responses of the brain," says Michelucci.

"However, because we suspect there are connections between the immune system and Parkinson's disease, we want to find out what happens in the brain when we trigger an immune response there." For this purpose, Michelucci brought cell cultures of microglial cells, the immune cells in the brain, into contact with specific constituents of bacterial membranes. The microglial cells exhibited a response and produced a cocktail of metabolic products.

This cocktail was subsequently analysed by Karsten Hillers metabolomics group. Upon closer examination, the scientists discovered that production of one substance in particular - itaconic acid - was upregulated. "Itaconic acid plays a central role in the plastics production. Industrial bioreactors use fungi to mass-produce it," says

Hiller: "The realisation that mammalian cells synthesise itaconic acid came as a major surprise."

However, it was not known how mammalian cells can synthesise this compound. Through sequence comparisons of the fungi's enzyme sequence to human protein sequences, Karsten Hiller then identified a human gene, which encodes a protein similar to the one in fungi: immunoresponsive gene 1, or IRG1 for short a most exciting discovery as the function of this gene was not known. Says Hiller: "When it comes to IRG1, there is a lot of uncharted territory. What we did know is that it seems to play some role in the big picture of the immune response, but what exactly that role was, we were not sure."

To change this situation, the team turned off IRG1 in cell cultures and instead added the gene to cells that normally do not express it. The experiments confirmed that in mammals, IRG1 codes for an itaconic acid-producing enzyme. But why? When immune cells like macrophages and microglial cells take up bacteria in order to inactivate them, the intruders are actually able to survive by using a special metabolic pathway called the glyoxylate shunt. According to Hiller, "macrophages produce itaconic acid in an effort to foil this bacterial survival strategy.

The acid blocks the first enzyme in the glyoxylate pathway. Which is how macrophages partially inhibit growth in order to support the innate immune response and digest the bacteria they have taken up." LCSB director Prof. Dr. Rudi Balling describes the possibilities that these insights offer: "Parkinson's disease is highly complex and has many causes. We now intend to study the importance of infections of the nervous system in this respect and whether itaconic acid can play a role in diagnosing and treating Parkinson's disease."


'/>"/>

Contact: karsten.hiller@uni.lu
karsten.hiller@uni.lu
352-466-644-6136
University of Luxembourg
Source:Eurekalert

Related biology news :

1. Team discovers how bacteria resist a Trojan horse antibiotic
2. Study discovers genetic pathway impacting the spread of cancer cells
3. NOAA discovers way to detect low-level exposure to seafood toxin in marine animals
4. New study discovers powerful function of single protein that controls neurotransmission
5. La Jolla Institute scientist discovers key step in immune system-fueled inflammation
6. NUS-led research team discovers how bacteria sense salt stress
7. Team discovers how western corn rootworm resists crop rotation
8. Team discovers reason that male moths can keep finding females
9. Study in mice discovers injection of heat-generating cells reduces belly fat
10. CSHL-led team discovers new way in which plants control flower production
11. International team discovers likely basis of birth defect causing premature skull closure in infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC ... today announced the opening of an IoT Center of ... strengthen and expand the development of embedded iris biometric ... unprecedented level of convenience and security with unmatched biometric ... one,s identity aside from DNA. EyeLock,s platform uses video ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
(Date:4/28/2016)... FRANCISCO and BANGALORE, India , ... of EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... provider, today announced a global partnership that will ... way to use mobile banking and payment services. ... is a key innovation area for financial services, but it ...
Breaking Biology News(10 mins):
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, doctors ... being treated for breast cancer benefitted from an injection of stem cells derived from ... frequent side effect of cancer treatment. , Lymphedema refers to the swelling ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 http://doi.org/10.17925/OHR.2016.12.01.22 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... on quality, regulatory and technical consulting, provides a free webinar on ... on July 13, 2016 at 12pm CT at no charge. , Incomplete investigations ...
Breaking Biology Technology: